Abstract: A gene editing system comprising: (a) a Type V CRISPR nuclease polypeptide or a first nucleic acid encoding the Type V CRISPR nuclease polypeptide; (b) a reverse transcriptase (RT) polypeptide or a second nucleic acid encoding the RT polypeptide; (c) a guide RNA (gRNA) or a third nucleic acid encoding the gRNA, wherein the gRNA comprises one or more binding sites recognizable by the Type V CRISPR nuclease (CRISPR nuclease binding sites) and a spacer sequence specific to a target sequence within a genomic site of interest, the target sequence being adjacent to a protospacer adjacent motif (PAM); and (d) a reverse transcription donor RNA (RT donor RNA) or a fourth nucleic acid encoding the RT donor RNA, wherein the RT donor RNA comprises a primer binding site (PBS) and a template sequence.

Abstract: The present invention provides a method for the detection of viable microorganisms in urine using DNA-crosslinking agent to differentiate between dead and live microorganisms. The DNA-crosslinking agent can penetrate cells which have compromised cell membranes, such as dead cells. The method of the present application comprises amplifying DNA in the urine sample which is pre-treated with the DNA-crosslinking agent. In addition, the method includes the step of centrifugation to remove supernatant from the urine.

Abstract: Methods are provided for the prevention and/or treatment of pain, interstitial cystitis and/or overactive bladder in a subject using an IPSE protein, such as H03 H-IPSE, H06 H-IPSE, M-IPSE or other IPSE homologs, variants, mutants or mimics. The IPSE protein can be administered prior to, contemporaneously with, and/or after the subject develops pain, interstitial cystitis and/or overactive bladder. Pharmaceutical compositions also are provided that contain one or more IPSE proteins in a pharmaceutically acceptable carrier, excipient or diluent.

Abstract: Methods are provided for the prevention and/or treatment of pain, interstitial cystitis and/or overactive bladder in a subject using an IPSE protein, such as H03 H-IPSE, H06 H-IPSE, M-IPSE or other IPSE homologs, variants, mutants or mimics. The IPSE protein can be administered prior to, contemporaneously with, and/or after the subject develops pain, interstitial cystitis and/or overactive bladder. Pharmaceutical compositions also are provided that contain one or more IPSE proteins in a pharmaceutically acceptable carrier, excipient or diluent.

Abstract: A method and system for assessing an amount of a blood component of a volume of fluid within a canister, the method comprising: receiving an image of the canister generated by the image acquisition device; selecting a first region of the image exhibiting substantially uniform color, wherein the first region of the image corresponds to a layer of fluid situated between a wall of the canister and a first feature of an insert retained in position within the canister; determining a color parameter representative of the first region; determining a concentration of a blood component within the canister, based upon the color parameter; upon determining the volume of fluid of fluid within the canister, generating an analysis informative of an amount of the blood component within the canister; and providing information derived from the analysis to an entity associated with an individual from whom the volume of fluid originated.

Abstract: A method and system for assessing an amount of a blood component of a volume of fluid within a canister, the method comprising: receiving an image of the canister generated by the image acquisition device; selecting a first region of the image exhibiting substantially uniform color, wherein the first region of the image corresponds to a layer of fluid situated between a wall of the canister and a first feature of an insert retained in position within the canister; determining a color parameter representative of the first region; determining a concentration of a blood component within the canister, based upon the color parameter; upon determining the volume of fluid of fluid within the canister, generating an analysis informative of an amount of the blood component within the canister; and providing information derived from the analysis to an entity associated with an individual from whom the volume of fluid originated.

Abstract: Methods for forming RX pads having gate alignment marks configured to enable noise reduction between layers while resulting in little or no non-uniformity of CMP processes for the IC, and the resulting devices, are disclosed. Embodiments include: providing, on a substrate, a RX pad having a SPM with a SPM horizontal and vertical positions at horizontal and vertical midpoints, respectively, of the first RX pad; providing a second RX pad abutting the first RX pad and a first STI pad abutting the second RX pad, each having a vertical midpoint at the SPM vertical position; forming a first gate alignment mark on the second RX pad and having vertical endpoints horizontally aligned with vertical endpoints of the second RX pad; and forming a second gate alignment mark on the first STI pad and having vertical endpoints horizontally aligned with vertical endpoints of the first STI pad.

Abstract: One method for estimating the extracorporeal blood volume in a portion of a physical sample includes: comparing a portion of an image of the sample with a template image of known extracorporeal blood volume indicator; tagging the portion of the image of the sample with a blood volume indicator according to the template image that is matched to the portion of the image of the sample; and estimating the extracorporeal blood volume in at least a portion of the physical sample, associated with the portion of the image of the sample, according to the blood volume indicator.

Abstract: Methods for forming RX pads having gate alignment marks configured to enable noise reduction between layers while resulting in little or no non-uniformity of CMP processes for the IC, and the resulting devices, are disclosed. Embodiments include: providing, on a substrate, a RX pad having a SPM with a SPM horizontal and vertical positions at horizontal and vertical midpoints, respectively, of the first RX pad; providing a second RX pad abutting the first RX pad and a first STI pad abutting the second RX pad, each having a vertical midpoint at the SPM vertical position; forming a first gate alignment mark on the second RX pad and having vertical endpoints horizontally aligned with vertical endpoints of the second RX pad; and forming a second gate alignment mark on the first STI pad and having vertical endpoints horizontally aligned with vertical endpoints of the first STI pad.

Abstract: One method for estimating the extracorporeal blood volume in a portion of a physical sample includes: comparing a portion of an image of the sample with a template image of known extracorporeal blood volume indicator; tagging the portion of the image of the sample with a blood volume indicator according to the template image that is matched to the portion of the image of the sample; and estimating the extracorporeal blood volume in at least a portion of the physical sample, associated with the portion of the image of the sample, according to the blood volume indicator.

Abstract: A package including a container and closure, and a method of authenticating same. In the package or a portion thereof, a marker material is dispersed into a base material and can be detected in the aftermarket by absorption spectroscopy to establish the authenticity of a product contained in the package.

Abstract: Example embodiments provide a mouse with a stabilizer. In particular embodiments, the stabilizer includes a U-shaped body which attaches to the bottom of the mouse so that the bottom surface of the U-shaped body forms a horizontal plane with the bottom surface of the mouse. In one embodiment, the U-shaped body includes a heel-rest portion and a pair of leg portions, one of which includes a thumb-rest and one of which includes a finger-rest. The leg portions define an opening for an opto-electric sensor such as a laser. In another embodiment, the stabilizer attaches to the rear of the mouse but does not extend forward to provide a thumb-rest or a finger-rest. In some embodiments, the stabilizer is fixedly attached or formed as part of the mouse, whereas in other embodiments it is detachable.

Abstract: A package including a container and closure, and a method of authenticating same. In the package or a portion thereof, a marker material is dispersed into a base material and can be detected in the aftermarket by absorption spectroscopy to establish the authenticity of a product contained in the package.

Abstract: A method of fabricating a dual-chamber plastic container in an injection/extrusion/blow-molding operation, in which a container finish is first injection molded. The finish mold tooling is then moved axially upwardly as plastic continues to be extruded through extrusion tooling in which an orifice bushing surrounds a mandrel tip. The mandrel tip has a passage through which plastic is extruded to form a wall that divides the extruded tube into separate chambers. Blow molds are brought in from both sides to capture the extruded tube, and air is blown through a passage in the finish mold tooling to blow the tube chambers to the confines of the mold.

Abstract: A method of fabricating a dual-chamber plastic container in an injection/extrusion/blow-molding operation, in which a container finish is first injection molded. The finish mold tooling is then moved axially upwardly as plastic continues to be extruded through extrusion tooling in which an orifice bushing surrounds a mandrel tip. The mandrel tip has a passage through which plastic is extruded to form a wall that divides the extruded tube into separate chambers. Blow molds are brought in from both sides to capture the extruded tube, and air is blown through a passage in the finish mold tooling to blow the tube chambers to the confines of the mold.

Abstract: The present invention relates to a method of inhibiting graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) patients by using L-leucyl-L-leucine methyl ester (LLME) to eliminate selective cytotoxic T cells in donor lymphocyte infusions (DLI). LLME has been shown to inhibit GVHD in animal models by selectively inducing apoptosis in natural killer cells and cytotoxic T cells. The application of LLME to the human clinical HSCT situation, however, has been hampered by HSC toxicity when unseparated marrow is treated at the concentrations necessary to purge GVHD-inducing T cells prior to infusion. In the present invention, this problem is circumvented by the LLME ex vivo treatment of DLI administered following transplantation of T cell-depleted HSC. In this setting, the effects of LLME on HSC contained within the DLI are irrelevant for clinical outcome.

Abstract: A high efficiency multi-image scanning method is disclosed. It involves the use of a special scanning window, or panel, containing a plurality of rectangular fields provided therein. The scanning window also contains a plurality of fiducial marks which associates each rectangular field, respectively, with a pre-defined location relative to the fiducial mark and a pre-defined scanning area. Prior to the scanning operation, a plurality of documents to be scanned are placed inside the rectangular fields. A pre-scan operation is performed to find and identify the fiducial mark. Then the scanner is moved to a selected rectangular field according to the information contained in the fiducial mark to scan an image having the pre-defined scanning area. Optionally, the method further contains the step of determining whether an image is present in the rectangular field, and if so, then adjusting the scanning area to compensate for any inadvertent misplacement of the image in the rectangular field.